ClinicalTrials.gg
CompletedNCT04712838Updated Oct 20, 2021

Study on the Bioavailability of SHR0302 in Healthy Subjects

A Phase 1 interventional study of SHR0302 and SHR0302 in Healthy Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The study is being conducted to evaluate the safety, and the relative bioavailability of SHR0302 tablets with three different formulations in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to sign an form before the start of the relevant activities of this trial, understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial protocol to complete this trial
  2. 18\~45 years old (including both ends, subject to when signing the informed consent form), healthy male
  3. Weight ≥ 50 kg, and (BMI): 19\~26 kg/m2 (including both ends)
  4. Those who have signed the informed consent and have no birth plan within 6 months after the last administration, and agree to take effective measures
  5. Able to communicate well with the researcher, and understand and comply with the requirements of this research

Exclusion criteria

Exclusion Criteria:

  1. Suspected of being allergic to the study drug or any ingredient in the study drug, or allergic
  2. Those who have participated in clinical trials of any drugs and medical devices within six months before screening (subject to the signed form)
  3. Subjects with any systemic inflammatory disease or disease
  4. Subjects with a history of recurrent herpes zoster, disseminated herpes zoster or disseminated herpes simplex
  5. Subjects with a history of malignant tumors
  6. Subjects with mental or neurological diseases, unwilling to communicate or have language barriers, unable to fully understand and cooperate
  7. Those who have a history of tuberculosis (TB) within six months before screening, or have clinical or imaging evidence of active or occult TB
  8. Routine blood examination during the screening period: white blood cell count \<3.0×109/L and/or \<1.5×109/L
  9. Subjects Those with serum creatinine> 1.5 mg/dL (133 μmol/L) at the time of screening
  10. At the time of screening, 12- check >450 ms or there are other abnormal conditions judged by the investigator to be
  11. Those who are positive for surface antigen, antibodies, syphilis antibodies, and antibodies
  12. Those who smoked more than 5 cigarettes daily in the 3 months before screening and cannot stop using any Tobacco products
  13. Those who drink regularly in the 6 months before screening, drink more than 14 units of alcohol per week (1 unit = 285 mL of beer, 25 mL of spirits, or 100 mL of wine) and cannot stop using any alcoholic products during the trial; those who have a positive alcohol breath test
  14. People who have a history of drug abuse, drug dependence or a positive urine drug abuse screening before administration, including: morphine, methamphetamine (methamphetamine), ketamine, cocaine, ecstasy (dimethylene) Dioxyamphetamine), cannabis (tetrahydrocannabinolic acid)
  15. Those who have had any surgery within 6 months before screening
  16. Infections that require antimicrobial (virus, bacterial, fungal, and parasitic infections) treatment that occurred within 4 weeks before screening
  17. Donated blood (or blood loss) within 3 months before screening and donated blood (or blood loss) ≥400 mL, or received blood transfusion
  18. Those who have had any acute disease that has been determined by the investigator to be clinically significant within 1 month before screening
  19. Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drugs; those who plan to take non-study drugs or health products during the trial period
  20. The 48 hours before the first dose until the end of the study, the subject refused to stop any methyl yellow Purine beverages or foods, such as coffee, tea, cola, chocolate, etc.; The 7 days before the first dose until the end of the study, the subject refused to stop using any beverages or foods containing grapefruit; there are special dietary requirements that cannot be consistent Eaters
  21. Physical examination, vital signs, laboratory examinations, chest X-ray or chest CT, abdominal ultrasound and other abnormal and clinically meaningful examination results
  22. The researcher believes that there are other subjects who are not suitable for participating in the research
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    group A

    Drug: SHR0302

  • Experimental
    group B

    Drug: SHR0302

  • Experimental
    group C

    Drug: SHR0302

  • Experimental
    group D

    Drug: SHR0302

  • Experimental
    group E

    Drug: SHR0302

  • Experimental
    group F

    Drug: SHR0302

Interventions

  • Group A subjects were given oral F1 、F2 and F3 version SHR0302

  • Group B subjects were given oral F1 、F3 and F2 version SHR0302

  • Group C subjects were given oral F2 、F1 and F3 version SHR0302

  • Group D subjects were given oral F2 、F3 and F1 version SHR0302

  • Group E subjects were given oral F3 、F1 and F2 version SHR0302

  • Group F subjects were given oral F3 、F2 and F1 version SHR0302

06

What researchers measure

Primary outcomes

  1. The peak plasma concentration (Cmax) of SHR0302.

    Based on the PK concentration data set, calculate the peak plasma concentration of SHR0302 by non-compartmental analysis.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose.

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of SHR0302.

    Based on the SHR0302 plasma concentration data set, calculate the Area Under the Plasma Concentration Versus Time Curve of SHR0302 by non-compartmental analysis.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose.

  3. The relative bioavailability of SHR0302 tablets with 3 different formulations.

    The mixed effect model is used to estimate the least square mean difference and 90% confidence interval between different formulations, and then take the antilog to obtain the estimate of the ratio of the least square geometric mean of the corresponding PK parameter and the 90% confidence interval Time.

    Time frame: through study completion, an average of 1 month.

Secondary outcomes

  1. The Peak Time (Tmax) of SHR0302.

    Based on the SHR0302 plasma concentration data set, calculate the time to reach peak plasma concentration of SHR0302 by non-compartmental analysis.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose.

  2. The Elimination half-life (T1/2) of SHR0302.

    Based on the SHR0302 plasma concentration data set, calculate the time required for the blood concentration of SHR0302 to drop by half.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose.

  3. The Clearance (CL/F) of SHR0302.

    Based on the SHR0302 plasma concentration data set, calculate the clearance of SHR0302 by non-compartmental analysis.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose.

  4. The apparent volume of distribution (Vz/F) of SHR0302.

    Based on the SHR0302 plasma concentration data set, calculate the apparent volume of distribution of SHR0302 by non-compartmental analysis.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours post-dose.

  5. Incidence of adverse events.

    laboratory abnormalities (based on hematology, biochemistry, coagulation function, and urinalysis tests), vital sign measurements (include blood pressure, pulse rate, respiratory rate, and body temperature) and 12-Lead electrocardiogram.

    Time frame: through study completion, an average of 1 month

07

Study locations

1 site
  • Xuanwu Hospital Beijing,Capital Medical University
    Beijing, Beijing 100053, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Apr 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 15, 2021
StartActual
Mar 15, 2021
Primary completionActual
Apr 13, 2021
CompletionActual
Apr 13, 2021
Last update
Oct 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04712838
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Mar 15, 2021
Primary completion
Apr 13, 2021
Completion
Apr 13, 2021
Last update
Oct 20, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion